Women are from venus: implications for diversified sex-based preexposure prophylaxis approaches

Affiliations

¹ Department of Health Sciences, Clinic of infectious Diseases and Tropical Medicine, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy.
² Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, CA, USA.

Comment

Giulia Marchetti et al. AIDS. 2021.

. 2021 Aug 1;35(10):1691-1693.

doi: 10.1097/QAD.0000000000002995.

¹ Department of Health Sciences, Clinic of infectious Diseases and Tropical Medicine, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy.
² Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, CA, USA.

No abstract available

Comment on

Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis.
Sekabira R, McGowan I, Yuhas K, Brand RM, Marzinke MA, Manabe YC, Frank I, Eron J, Landovitz RJ, Anton P, Cranston RD, Anderson P, Mayer KH, Amico KR, Wilkin TJ, Chege W, Kekitiinwa AR, McCauley M, Gulick RM, Hendrix CW. Sekabira R, et al. AIDS. 2021 Aug 1;35(10):1585-1595. doi: 10.1097/QAD.0000000000002907. AIDS. 2021. PMID: 33831911 Free PMC article.

1. UNAIDS. 2025 AIDS Targets. https://www.unaids.org/en/topics/2025_target_setting .
1. McGowan I, Wilkin T, Landovitz RJ, Wu C, Chen Y, Marzinke MA, et al. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing preexposure prophylaxis regimens in MSM . AIDS 2019; 33:237–246.
1. Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, Adler A, et al. First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy . PLoS One 2011; 6:e23243doi: 10.1371/journal.pone.0023243. - DOI
1. Mcgowan I, Cranston RD, Duffill K, Siegel A, Engstrom JC, Nikiforov A, et al. A phase 1 randomized, open label, rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of three formulations of tenofovir 1% gel (the CHARM-01 Study) . PLoS One 2015; 10:e0125363doi: 10.1371/journal.pone.0125363. - DOI
1. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial . Lancet 2013; 381:2083–2090.